Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

XTLB | XTL Biopharmaceuticals Ltd.

Index- P/E- EPS (ttm)-0.51 Insider Own1.00% Shs Outstand5.45M Perf Week8.92%
Market Cap5.33M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.66M Perf Month23.20%
Income-2.80M PEG- EPS next Q- Inst Own8.40% Short Float / Ratio0.16% / 0.97 Perf Quarter-17.20%
Sales- P/S- EPS this Y-447.90% Inst Trans-0.92% Short Interest0.01M Perf Half Y-16.53%
Book/sh0.57 P/B1.82 EPS next Y- ROA-61.10% Target Price- Perf Year-30.54%
Cash/sh0.56 P/C1.84 EPS next 5Y- ROE-63.80% 52W Range0.75 - 1.54 Perf YTD-14.46%
Dividend- P/FCF- EPS past 5Y-8.30% ROI- 52W High-32.79% Beta1.04
Dividend %- Quick Ratio12.20 Sales past 5Y- Gross Margin- 52W Low38.00% ATR0.10
Employees- Current Ratio12.20 Sales Q/Q- Oper. Margin- RSI (14)55.76 Volatility3.95% 9.10%
OptionableNo Debt/Eq0.00 EPS Q/Q-285.70% Profit Margin- Rel Volume0.85 Prev Close0.85
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume7.70K Price1.03
Recom- SMA208.62% SMA5011.89% SMA200-11.77% Volume6,564 Change22.17%
Date Action Analyst Rating Change Price Target Change
May-08-15Initiated H.C. Wainwright Buy $6
Nov-21-18 08:00AM
Nov-01-18 10:09AM
Jul-24-18 09:09AM
May-29-18 05:37PM
Dec-13-17 07:30AM
12:08PM Loading…
Dec-06-17 12:08PM
Nov-27-17 10:30AM
Oct-23-17 11:23AM
Oct-06-17 07:30AM
Oct-05-17 07:50AM
Sep-26-17 09:23AM
Sep-12-17 09:00AM
Jul-11-17 07:00AM
Jun-15-17 09:00AM
Apr-27-17 09:50AM
09:10AM Loading…
Apr-05-17 09:10AM
Mar-30-17 08:55AM
Mar-22-17 09:22AM
Mar-07-17 12:40PM
Mar-01-17 08:30AM
Feb-17-17 08:00AM
Feb-13-17 09:08AM
Jan-25-17 08:30AM
Jan-05-17 08:30AM
Dec-19-16 08:00AM
Dec-06-16 08:30AM
Nov-09-16 01:25PM
Sep-27-16 08:30AM
Sep-07-16 08:32AM
08:00AM Loading…
Sep-06-16 08:00AM
Aug-11-16 09:00AM
Jun-02-16 09:11AM
Jun-01-16 08:30AM
May-16-16 11:45AM
Apr-07-16 01:04PM
Mar-31-16 09:45AM
Mar-21-16 08:30AM
Mar-09-16 08:29AM
Mar-02-16 09:00AM
Feb-22-16 09:02AM
Feb-10-16 08:30AM
Jan-27-16 08:30AM
Jan-25-16 08:30AM
Jan-13-16 08:30AM
Jan-11-16 08:30AM
Dec-01-15 08:30AM
Nov-09-15 08:30AM
Oct-28-15 09:00AM
Oct-26-15 09:15AM
Oct-13-15 08:45AM
Sep-17-15 11:40AM
Sep-03-15 09:00AM
Sep-01-15 09:00AM
Aug-26-15 09:00AM
Jun-01-15 08:00AM
May-11-15 10:50AM
May-09-15 09:45AM
May-08-15 09:35AM
Apr-28-15 07:45AM
Mar-31-15 09:30AM
Feb-17-15 08:30AM
Dec-30-14 12:23PM
Dec-08-14 08:30AM
Dec-01-14 08:00AM
Sep-02-14 12:09PM
Jul-22-14 02:54PM
Jul-16-14 09:18AM
Jun-12-14 08:00AM
Jun-02-14 09:00AM
May-19-14 08:00AM
Apr-02-14 04:41PM
Mar-25-14 08:00AM
Jan-08-14 08:00AM
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.